Jazz Pharmaceuticals (NASDAQ: JAZZ) — Company Overview, News & Financial Data
Jazz Pharmaceuticals develops innovative medicines for sleep disorders and oncology, aiming to address unmet medical needs.
Jazz Pharmaceuticals
Jazz Pharmaceuticals is a global biopharmaceutical company focused on developing, commercializing, and manufacturing therapeutic products for patients with severe medical conditions, primarily in neuroscience and oncology. Headquartered in Dublin, Ireland, the company operates commercial and operational facilities in the United States, Europe, and internationally. Its neuroscience portfolio includes treatments for sleep disorders such as narcolepsy and idiopathic hypersomnia, as well as cannabinoid-based therapies for rare pediatric epilepsy syndromes. In oncology and hematology, its commercial offerings focus on acute lymphoblastic leukemia, acute myeloid leukemia, small cell lung cancer, and hepatic veno-occlusive disease.
Snapshot
Operations
Products and/or services of Jazz Pharmaceuticals
- Sleep Disorder Therapeutics: Commercialization and delivery of low-sodium oxybate oral solution formulations designed for the treatment of cataplexy and excessive daytime sleepiness in patients living with narcolepsy or idiopathic hypersomnia across North American and European healthcare markets.
- Cannabinoid Epilepsy Therapies: Production and distribution of purified plant-derived cannabidiol oral solutions indicated for controlling severe epileptic seizures associated with Lennox-Gastaut syndrome, Dravet syndrome, and tuberous sclerosis complex in pediatric and adult patient populations globally.
- Recombinant Oncology Therapies: Manufacturing and supply of recombinant erwinia asparaginase enzyme therapies developed to treat acute lymphoblastic leukemia and lymphoblastic lymphoma in patients who have developed hypersensitivity or silent inactivation to E. coli-derived asparaginase products.
- Small Cell Lung Cancer Treatments: Provision of selective transcription inhibitors formulated to treat metastatic small cell lung cancer in adult patients whose disease has progressed on or after prior platinum-based chemotherapy regimens across clinical and hospital network settings.
- Severe Veno-Occlusive Disease Therapies: Development and commercial distribution of defibrotide sodium oligonucleotide therapeutics indicated for severe hepatic veno-occlusive disease with renal or pulmonary dysfunction following hematopoietic stem cell transplantation in adult and pediatric clinical care environments.
- Liposomal Chemotherapy Formulations: Distribution of liposomal combination chemotherapy encapsulating daunorubicin and cytarabine at a fixed molar ratio, designed for the treatment of newly diagnosed therapy-related acute myeloid leukemia or acute myeloid leukemia with myelodysplasia-related changes.
Jazz Pharmaceuticals executive team
- Mr. Bruce C. CozaddCo-Founder & Chairman
- Ms. Renee D. GalaPresident, CEO & Director
- Mr. Philip L. JohnsonExecutive VP & CFO
- Ms. Patricia CarrSenior VP & Chief Accounting Officer
- Dr. Robert Iannone M.D.Executive VP, Chief Medical Officer and Global Head of Research & Development
- Ms. Samantha PearceExecutive VP & Chief Commercial Officer
- Jack W. SpinksExecutive Director of Investor Relations
- Ms. Neena M. Patil J.D.Executive VP & Chief Legal Officer
- Ms. Heidi MannaExecutive VP & Chief People Officer
- Dr. Jed Black M.D.Senior Vice President of Sleep & CNS Medicine